<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139594">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01954082</url>
  </required_header>
  <id_info>
    <org_study_id>NICHD-NRN-0053</org_study_id>
    <secondary_id>U10HD021364</secondary_id>
    <secondary_id>U10HD040689</secondary_id>
    <secondary_id>U10HD021385</secondary_id>
    <secondary_id>U10HD027851</secondary_id>
    <secondary_id>U10HD027853</secondary_id>
    <secondary_id>U10HD027856</secondary_id>
    <secondary_id>U10HD027904</secondary_id>
    <secondary_id>U10HD027880</secondary_id>
    <secondary_id>U10HD034216</secondary_id>
    <secondary_id>U10HD021373</secondary_id>
    <secondary_id>U10HD040492</secondary_id>
    <secondary_id>U10HD053109</secondary_id>
    <secondary_id>U10HD053089</secondary_id>
    <secondary_id>U10HD068244</secondary_id>
    <secondary_id>U10HD068263</secondary_id>
    <secondary_id>U10HD068270</secondary_id>
    <secondary_id>U10HD068278</secondary_id>
    <secondary_id>U10HD068284</secondary_id>
    <secondary_id>U10HD036790</secondary_id>
    <nct_id>NCT01954082</nct_id>
  </id_info>
  <brief_title>Inositol to Reduce Retinopathy of Prematurity</brief_title>
  <acronym>INS-3</acronym>
  <official_title>INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, randomized, double-masked, placebo-controlled study designed to determine
      the effectiveness of myo-Inositol 5% Injection to increase the incidence of survival without
      severe Retinopathy of Prematurity (ROP) through acute/final ROP determination up to 55 weeks
      postmenstrual age (PMA) in premature infants &lt;28 0/7 weeks' gestation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 1760 infants are to be enrolled at approximately 18 NICHD Neonatal Research
      Network (NRN) Centers (approximately 44 sites) in the United States. Infants meeting the
      study selection criteria and for whom informed consent is obtained will be randomized to
      receive either 80 mg inositol/kg/day or placebo, administered in divided doses every 12
      hours (40 mg/kg/dose). Study drug will be administered daily, starting within 12 to 72 hours
      of birth and continued until the earliest of 34 weeks PMA, 10 weeks chronologic age, or the
      time of hospital discharge or transfer. Inositol or placebo will be administered IV until
      enteral feedings reach 120ml/kg/day (or sooner if the infant is no longer receiving IV
      fluids), at which time the same dose and formulation will be administered enterally every 12
      hours.

      For publication purposes, the analysis of the primary efficacy outcome will consider the
      entire study population. In support of a new drug application (NDA) for use of myo-Inositol
      5% Injection to increase survival without severe ROP through the determination of
      acute/final ROP status, the analysis of the primary efficacy outcome will be conducted for
      the entire study population and separately within pre-specified regulatory sub-studies
      created by administratively splitting infants enrolled at each study center into two
      sub-studies.

      Assessments performed during the study include customary newborn intensive care procedures
      including repeat eye examinations until ROP status is final (which often extends after
      discharge), measurements of growth, cranial ultrasounds or other imaging per usual practice,
      and the collection of clinical diagnoses throughout hospitalization to evaluate other common
      morbidities of extreme preterm birth. Adverse events will be recorded from time of treatment
      initiation until 7 days after the last dose of study drug, and concurrent medications will
      be recorded from 24 hours prior to randomization until 7 days after the last dose of study
      drug or until discharge or transfer if sooner. Using the separate NICHD Follow-up protocol,
      longer term data will be collected at 22-26 months corrected age, including growth,
      neurodevelopmental testing, overall health status, rehospitalizations, surgeries and
      diagnoses, including ophthalmic diagnoses and treatments since discharge.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Survival without severe Retinopathy of Prematurity (ROP)</measure>
    <time_frame>by 55 weeks PMA</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary outcome is survival without severe ROP through Acute/Final ROP status determination (favorable) versus development of severe ROP or death prior to reaching Acute/Final ROP status (unfavorable) followed up to 55 weeks PMA.
Death in relation to the primary variable will be defined as from any cause before Acute/Final ROP status is determined.
Favorable Acute/Final ROP status requires that no ROP, or only mild ROP has occurred in both eyes and that the eyes have matured beyond the risk of developing severe ROP.
Unfavorable ROP determination requires that one or both eyes reach ROP severity warranting intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary Dysplasia (BPD)</measure>
    <time_frame>36 weeks PMA</time_frame>
    <safety_issue>No</safety_issue>
    <description>NICHD Physiologic Definition: Requiring oxygen to maintain an oxygen saturation of 90% or greater while breathing room air at 36 weeks PMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BPD or Death from BPD</measure>
    <time_frame>prior to 37 weeks PMA</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>BPD (Physiologic Definition) or Death from BPD prior to 37 weeks PMA, with cause of death certified by the Center PI as the primary cause, or a significant co-contributing cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>22 - 26 months age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as death from any cause following randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any ROP</measure>
    <time_frame>by 55 weeks PMA</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any ROP: defined as ROP of any severity that is observed on at least 2 examinations in either eye through the time that Acute/Final ROP status is reached.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type 2 ROP</measure>
    <time_frame>by 55 weeks PMA</time_frame>
    <safety_issue>No</safety_issue>
    <description>Type 2 ROP through the time that Acute/Final ROP status is reached: defined as 1 or both eyes reaching Type 2 ROP (ETROP 2003), but not Type 1.
Type 2 ROP is defined as: (ETROP 2003).
in Zone II: Stage 3 ROP without Plus Disease, or
in Zone I: Stage 1 or 2 ROP without Plus Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe IVH</measure>
    <time_frame>approximately 1 to 6 weeks after birth</time_frame>
    <safety_issue>No</safety_issue>
    <description>IVH Grades 3 or 4 on either side of the brain, or extensive PVL. IVH will be classified as described by Papile (Papile 1978). PVL will be graded by the characteristics of the periventricular white matter on ultrasound or MRI done between 4 to approximately 6 weeks after birth per usual care (Barkovich 2000) and/or porencephalic cyst.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The occurrence of adverse events and serious adverse events</measure>
    <time_frame>7 days post study drug discontinuation</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Necrotizing Enterocolitis (NEC)</measure>
    <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Stage II or worse, whether treated (medically or surgically) and if the infant survived (modified Bell's classification [Walsh 1986]).</description>
  </other_outcome>
  <other_outcome>
    <measure>Isolated gastrointestinal perforation</measure>
    <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>judged not to be due to NEC</description>
  </other_outcome>
  <other_outcome>
    <measure>Late onset sepsis</measure>
    <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>culture positive septicemia/bacteremia (≥72 hours of age) treated with antibiotics for ≥ 5 days or died before treatment was completed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patent Ductus Arteriosus (PDA)</measure>
    <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Occurrence of clinically significant patent ductus arteriosus (PDA), and if received intervention with prostaglandin inhibitors, and/or surgery.</description>
  </other_outcome>
  <other_outcome>
    <measure>Seizures</measure>
    <time_frame>NRN infant status, i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Seizures treated with an anticonvulsant for &gt;72 hours</description>
  </other_outcome>
  <other_outcome>
    <measure>Total days on parenteral nutrition</measure>
    <time_frame>NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Total days on parenteral nutrition (including amino acids and/or lipids)</description>
  </other_outcome>
  <other_outcome>
    <measure>Days on oxygen, days on ventilator</measure>
    <time_frame>NRN infant status  i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Hearing Loss</measure>
    <time_frame>NRN infant status  i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hearing loss as defined as never passing a hearing screening in one or both ears</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurodevelopment</measure>
    <time_frame>22-26 months corrected age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Neurodevelopment at 22-26 months corrected age (i.e., 22-26 months past due date) using the Bayley Scales of Infant Development III.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vision loss</measure>
    <time_frame>22-26 Months Corrected Age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vision loss as diagnosed by an ophthalmologist as legally blind, and subdivided into &quot;ophthalmic origin&quot;, or &quot;not ophthalmic origin&quot; (i.e., cortical blindness is non-ophthalmic in origin and indicates that there is no retinal detachment or other abnormal fundus or ocular finding, except optic atrophy. Such cases will be considered central [neurologic] in origin.)</description>
  </other_outcome>
  <other_outcome>
    <measure>Hearing loss</measure>
    <time_frame>22-26 Months Corrected Age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hearing loss requiring that hearing aids be prescribed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cerebral palsy</measure>
    <time_frame>22-26 Months Corrected Age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cerebral palsy by severity category (absent/mild/moderate/severe).</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall health status</measure>
    <time_frame>22-26 Months Corrected Age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall health status per recall from the parent/guardian (including survival, re-hospitalizations, surgeries, ongoing medications, and chronic illnesses).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1760</enrollment>
  <condition>Retinopathy of Prematurity (ROP)</condition>
  <arm_group>
    <arm_group_label>myo-Inositol 5% Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 12-72 hours of birth, infants will receive 80 mg myo-inositol 5% Injection per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5% glucose(dextrose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Within 12-72 hours of birth, infants will receive 80 mg 5% glucose(dextrose) USP for intravenous infusion per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>myo-Inositol 5% Injection</intervention_name>
    <description>Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.
Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose).</description>
    <arm_group_label>myo-Inositol 5% Injection</arm_group_label>
    <other_name>Inositol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inborn or out born infants of either gender or any race with best obstetrical
             estimate of gestation &lt;28 weeks (27 6/7 weeks and younger). Gestational age will be
             determined by best obstetrical estimate using the hierarchy of best obstetrical
             estimate using early ultrasound dating, maternal menstrual dating confirmed by
             examination, or neonatal gestational age assessment by physical examination.

          -  Alive at 12 hours.

          -  Age in hours up to 72 hours, although we will seek enrollment as early as feasible
             after consent and 12 hours.

          -  Informed consent signed and dated by parent and/or guardian, which includes
             likelihood of completing follow-up ophthalmic examinations as an outpatient, and
             long-term follow-up.

        Exclusion Criteria

          -  Major congenital malformations

          -  Congenital malformations of the eye identified prior to randomization.

          -  Overt evidence of intrauterine congenital infections (&quot;TORCH&quot;) or life threatening
             impairment of renal, hepatic, or cardiac function (considered moribund).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>72 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele C Walsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University, Rainbow Babies and Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abhik Das, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTI International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seetha Shankaran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara J Stoll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Schibler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Children's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brenda B Poindexter, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abbot R Laptook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University, Women &amp; Infants Hospital of Rhode Island</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krisa P Van Meurs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waldemar A Carlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen A Kennedy, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald N Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward F Bell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dale L Phelps, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl T D'Angio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Truog, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital-Kansas City, MO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leif Nelin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute at Nationwide Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uday Devaskar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myra Wyckoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas at Southwestern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristi L Watterberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Schmidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dale L. Phelps, MD</last_name>
    <phone>707-897-9063</phone>
    <email>Dale_Phelps@URMC.Rochester.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosemary D. Higgins, MD</last_name>
    <phone>301-435-7909</phone>
    <email>higginsr@mail.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Waldemar A. Carlo, MD</last_name>
      <phone>205-934-4680</phone>
      <email>wcarlo@peds.uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Monica V. Collins, RN BSN</last_name>
      <phone>(205) 934-5771</phone>
      <email>mcollins@peds.uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Waldemar A. Carlo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Uday Devaskar, MD</last_name>
      <phone>310-825-9357</phone>
      <email>udevaskar@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Teresa Chanlaw, BS</last_name>
      <phone>(310) 794-4972</phone>
      <email>tchanlaw@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Uday Devaskar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krisa P. Van Meurs, MD</last_name>
      <phone>650-723-5711</phone>
      <email>vanmeurs@leland.stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>M. Bethany Ball, BS CCRC</last_name>
      <phone>(650) 725-8342</phone>
      <email>mbball@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Krisa P. Van Meurs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara J. Stoll, MD</last_name>
      <phone>404-727-5740</phone>
      <email>barbara_stoll@oz.ped.emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Hale, RN BS</last_name>
      <phone>(404) 616-4218</phone>
      <email>ellen_hale@oz.ped.emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Barbara J. Stoll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brenda B. Poindexter, MD MS</last_name>
      <phone>317-274-3592</phone>
      <email>bpoindex@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>Leslie D. Wilson, RN BSN</last_name>
      <phone>(317) 274-8255</phone>
      <email>ldw@iupui.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Brenda B. Poindexter, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edward F. Bell, MD</last_name>
      <phone>319-356-4006</phone>
      <email>edward-bell@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen J. Johnson, RN BSN</last_name>
      <phone>(319) 356-2924</phone>
      <email>karen-johnson@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Edward F. Bell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seetha Shankaran, MD</last_name>
      <phone>313-580-4452</phone>
      <email>sshankar@med.wayne.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Bara, RN BSN</last_name>
      <phone>(313) 745-1436</phone>
      <email>rbara@med.wayne.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Seetha Shankaran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Truog, MD</last_name>
      <phone>816-234-3592</phone>
      <email>wtruog@cmh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cheri Gauldin, BSN</last_name>
      <phone>(816) 234-3920</phone>
      <email>cagauldin@cmh.edu</email>
    </contact_backup>
    <investigator>
      <last_name>William Truog, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristi L. Watterberg, MD</last_name>
      <phone>505-272-3967</phone>
      <email>kwatterberg@salud.unm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Conra Backstrom Lacy, RN</last_name>
      <phone>(505) 272-0367</phone>
      <email>cbackstrom@salud.unm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kristi L. Watterberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl T D'Angio, MD</last_name>
      <phone>585-273-4911</phone>
      <email>carl_dangio@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Holly Wadkins</last_name>
      <phone>585-275-0218</phone>
      <email>Holly_Wadkins@urmc.rochester.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carl T D'Angio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronald N. Goldberg, MD</last_name>
      <phone>919-681-6025</phone>
      <email>goldb008@mc.duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joanne Finkle, BSN</last_name>
      <phone>919-681-4911</phone>
      <email>j.finkle@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ronald N. Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>C. Michael Cotten, MD MHS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RTI International</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abhik Das, PhD</last_name>
      <phone>301-770-8214</phone>
      <email>adas@rti.org</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Zaterka-Baxter, RN</last_name>
      <phone>(919) 485-7750</phone>
      <email>kzaterka@rti.org</email>
    </contact_backup>
    <investigator>
      <last_name>Abhik Das, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kurt Schibler, MD</last_name>
      <phone>513-636-3972</phone>
      <email>kurt.schibler@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Cathy Grisby, BSN CCRC</last_name>
      <phone>(513) 558-4953</phone>
      <email>grisbyca@email.uc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kurt Schibler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University, Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele C. Walsh, MD MS</last_name>
      <phone>216-844-3759</phone>
      <email>mcw3@cwru.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nancy S. Newman, BA RN</last_name>
      <phone>(216) 368-3084</phone>
      <email>nxs5@cwru.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michele C. Walsh, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Institute at Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leif Nelin, MD</last_name>
      <phone>614-722-3030</phone>
      <email>Leif.Nelin@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Chris Fortney, MS, RN</last_name>
      <phone>614-722-6489</phone>
      <email>christine.fortney@nationwidechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Leif Nelin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristy of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Schmidt, MD</last_name>
      <phone>215-662-3228</phone>
      <email>barbara.schmidt@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Aasma Chaudhary, BS</last_name>
      <phone>215-615-5442</phone>
      <email>aasma.chaudhary@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Barbara Schmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University, Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abbot R. Laptook, MD</last_name>
      <phone>401-274-1122</phone>
      <email>alaptook@WIHRI.org</email>
    </contact>
    <contact_backup>
      <last_name>Angelita Hensman</last_name>
      <phone>(401) 274-1122</phone>
      <email>ahensman@wihri.org</email>
    </contact_backup>
    <investigator>
      <last_name>Abbot R. Laptook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pablo J. Sanchez, MD</last_name>
      <phone>214-648-3753</phone>
      <email>Pablo.Sanchez@UTSouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diana M. Vasil, RNC-NIC</last_name>
      <phone>(214) 648-3789</phone>
      <email>Diana.Vasil@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pablo J. Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen A. Kennedy, MD MPH</last_name>
      <phone>713-500-6708</phone>
      <email>Kathleen.A.Kennedy@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Georgia E. McDavid, RN</last_name>
      <phone>(713) 500-5734</phone>
      <email>Georgia.E.McDavid@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathleen A. Kennedy, MD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon E. Tyson, MD MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://neonatal.rti.org/</url>
    <description>NICHD NRN Website</description>
  </link>
  <link>
    <url>http://www.nichd.nih.gov/about/org/cdbpm/pp/index.cfm</url>
    <description>NICHD Pregnancy &amp; Perinatology Branch</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinopathy</keyword>
  <keyword>Prematurity</keyword>
  <keyword>Infant, Newborn, Diseases</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
